SGK1 and plasma cell myeloma: For example, increased expression and/or activity of SGK-1 is reported for several human tumors including those involving the breast, tongue, head and neck (e.g., squamous cell carcinoma), ovarian, prostate, multiple myeloma and non-small cell lung cancer (36–43).